Clinical Studies

      Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study

      First posted
      Jan 31, 2013
      Identifier
      NCT01780298
      Publication Site URL
      Topic
      Official Title

      A Biomarker Study to Compare Gene and Protein Expression Profiles in Four Separate Groups of Subjects Including COPD Cases (GOLD Stage 1-2 and Current Smokers With a ≥ 10 Pack Year Smoking History) and Three Control Groups of Matched Non-smoking Subjects (Never Smoked), Ex-smokers and Current Smokers, to Identify Novel Biomarkers, to Assess Standard Biomarkers of Inflammation and to Compare Inflammatory Cell Responses and Selected Markers of Inflammation in Blood, Induced Sputum and Nasal Samples.

      Brief Summary

      Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history. The disease is characterized by an increase in numbers of airway white blood cells (neutrophils, lymphocytes and monocytes). Stimulation of white blood cells results in the release of different agents of inflammation. Some of these agents give an indication of the presence or severity of a disease when measured.This case control study will be conducted at The Heart Lung Centre, London, UK. The study aims to determine biomarkers for the differentiation of subjects with COPD (GOLD Stage 1-2 and who are current smokers with a ≥ 10 pack year smoking history) and three matched control groups: one of non-smoking subjects (never smoked), one of ex-smokers and one of current smokers. COPD subjects will be matched to the non-COPD subjects by gender, age and ethnicity.The study will include a range of physiological measurements including lung function, computerized tomography scans (CT scans), cardio pulmonary exercise test and computerized multichannel lung sounds analysis (Stethographics). In addition, lung inflammation will be assessed by cellular and molecular biomarkers using, e.g., transcriptomics and proteomics technologies.

      Summary

      Recruitment: Completed

      Study Results: Submitted

      Enrollment: 739

      Study Type: Observational

      Other IDs: QASMC 202

      Related Publications

      Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking

      Clinical

      Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

      Clinical

      Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in Japan: A comparison with continued cigarette use or smoking abstinence

      Clinical

      Reduced Exposure To Harmful And Potentially Harmful Constituents after 90 Days Of Use Of Tobacco Heating System 2.2 Menthol In Japan: A Comparison With Continued Cigarette Use Or Smoking Abstinence

      Clinical

      Psychometric Evaluation of the mCEQ applied to Cigarettes and Heat-Not-Burn Products in the US and Japan

      Clinical

      Pharmacokinetics Of Nicotine And Subjective Effects Following The Single Use Of A Non-Menthol And Menthol Version Of Tobacco Heating System 2.2 In Two Studies In Japan: A Comparison With Single Use Of A Combustible Cigarette And Nicotine Gum

      Clinical

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.